PURPOSE: To investigate @entity5 heterogeneity in the recurrence of @entity43 demonstrated by polycomb group (PcG) proteins. METHODS: Tissue microarrays containing matched primary and recurrent @entity43 from the same @entity1 were constructed for detection of PcG protein expression. Survival analyses of clinicopathological parameters and expression of PcG proteins were performed on progression-free survival (PFS) and @entity1349 ( @entity1349 ) of @entity1 . Genetic and epigenetic heterogeneity was explored in aspects of gene copy number and microRNA (miRNA) profiling. RESULTS: PcG proteins were heterogeneously expressed in primary versus recurrent @entity5 (P<0.05). In univariate survival analysis of the @entity43 cohorts, a significant association of intensive expression of @entity3752 and @entity16719 in first-onset lymph node @entity3 with shortened PFS was demonstrated (P=0.010, P=0.019); and a significant association of intensive expression of @entity3752 and @entity16719 in recurrent @entity5 with shortened @entity1349 was demonstrated (P=0.042, P=0.047). Importantly, @entity3752 and @entity16719 expression provided significant independent prognostic parameters in multivariate analyses (P<0.05). Gene amplification did not always coincide with PcG protein expression. Eight miRNAs were found to be downregulated in recurrent @entity5 , among which @entity68144 might indirectly regulate the expression of @entity16719 through transcription factor @entity49944 . CONCLUSION: @entity5 heterogeneity exists in the recurrence of @entity43 , manifested by PcG protein expression and underlying genetic and epigenetic alterations. Intensive expression of @entity3752 and @entity16719 are predictors of earlier relapse and @entity1349 , independent of grade and chemotherapy sensitivity. @entity16719 and @entity68144 have great potential to be new targets for treatment of recurrent @entity43 .

@entity5 heterogeneity in the recurrence of XXXX demonstrated by polycomb group proteins.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian tumors', 'ovarian carcinoma', 'ovarian cancer', 'epithelial ovarian cancer'] @entity49944 :: ('3609', 'Gene') :: ['ILF3'] @entity68144 :: ('100126296', 'Gene') :: ['miR-298'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'tumors'] @entity3752 :: ('648', 'Gene') :: ['BMI1'] @entity16719 :: ('2146', 'Gene') :: ['EZH2'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'shorter OS', 'overall survival']
@entity43 :: (MESH:D010051,Disease) :: ['epithelial ovarian cancer']
